DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report released on Friday,Benzinga reports. They currently have a $7.00 target price on the stock.

Separately, Oppenheimer reiterated an “outperform” rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, August 16th.

DiaMedica Therapeutics Stock Performance

NASDAQ DMAC opened at $4.01 on Friday. The stock has a market capitalization of $171.47 million, a P/E ratio of -7.16 and a beta of 1.46. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $4.95. The stock has a fifty day moving average of $4.30 and a 200-day moving average of $3.58.

Institutional Trading of DiaMedica Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DMAC. Geode Capital Management LLC boosted its position in shares of DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after purchasing an additional 70,070 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in DiaMedica Therapeutics during the third quarter worth about $40,000. Blue Trust Inc. acquired a new position in shares of DiaMedica Therapeutics during the 3rd quarter worth about $185,000. Magnolia Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics in the 2nd quarter valued at about $87,000. Finally, Vanguard Group Inc. raised its position in shares of DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after acquiring an additional 211,351 shares during the period. Institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.